## THE EDUCATION EVOLUTION



This issue marks the beginning of GT's 15th year. It is the first recurring news publication devoted to advancing the care of glaucoma patients. In January 2003, the debut issue (bit.ly/vold0117) celebrated the FDA approval of latanoprost as a first-line glaucoma therapy. The Ocular Hypertension Treatment Study (OHTS), Early Manifest

Glaucoma Trial (EMGT), and Advanced Glaucoma Intervention Study (AGIS) were key topics of discussion, and Ciba Vision was introducing the Optonol Ex-Press glaucoma minishunt to surgeons. Theodore Krupin, MD, was the first glaucomatologist profiled in "5 Questions," a well-received column discontinued in 2015.

At the outset, GT was exclusively digital, but it has evolved into a multimedia offering of issues available in print and digital formats, surgical videos, and digital series such as Glaucoma Today Journal Club. Under the guidance of the editorial board and readership, we seek to deliver a wellbalanced, cutting-edge, accurate, practical, and highly ethical publication that serves as a valuable, first-line glaucoma resource to physicians. To that end, the current edition faces today's information explosion by focusing on how doctors pursue and receive medical education.

One of GT's long-standing strengths is the editorial leadership provided by Gillian McDermott, who has served as the publication's Editor-in-Chief since its inception. Educating physicians regarding the diagnosis and management of

glaucoma patients has been one of her life's passions and remains a focus of her professional career to this day. Her efforts to grow and maintain a diverse authorship team, keep opinions and topics relevant yet well balanced, avoid conflicts of interest whenever possible, and demand a high quality of writing and content while maintaining a consistent editorial format in the publication are impressive. These achievements alone are to be celebrated and deeply admired. For me personally, however, what sets her apart is who she is as a person. Gillian is compassionate, caring, patient, and pleasant, and I consider her to be one of the finest individuals and friends I have ever known.

As GT continues to strive to meet our readers' educational needs, I would like to take this opportunity to solicit your recommendations on how we can best serve you. The proliferation of therapeutic options and research data can be overwhelming. Our goal is to navigate the sea of information to provide accurate and practical information that will allow you to excel in your chosen profession and maintain a balanced lifestyle while reducing your need to look elsewhere. We look forward to hearing from you. Happy new year!

Steven D. Vold, MD

Steven D. Vold, MD **Chief Medical Editor**